Page last updated: 2024-12-11

angoroside c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

angoroside C: angoroside C is the (E)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23757181
MeSH IDM0370164

Synonyms (22)

Synonym
ACON1_000575
MEGXP0_000467
angoroside c
NCGC00168947-01
BRD-K07160755-001-01-5
115909-22-3
S9407
8g0i99w72t ,
unii-8g0i99w72t
ginsengmax
beta.-d-glucopyranoside, 2-(3-hydroxy-4-methoxyphenyl)ethyl o-.alpha.-l-arabinopyranosyl-(1-6)-o-(6-deoxy-.alpha.-l-mannopyranosyl-(1-3))-, 4-((2e)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate)
angoroside c [inci]
AC-33990
AKOS037514548
AS-75316
(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxan-3-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
HY-N0062
CS-0007110
CCG-270469
beta-d-glucopyranoside, 2-(3-hydroxy-4-methoxyphenyl)ethyl o-alpha-l-arabinopyranosyl-(1-->6)-o-[6-deoxy-alpha-l-mannopyranosyl-(1-->3)]-, 4-[(2e)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate]
Q27270356
[(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]